Medical grads abandon internships, robbing hospitals of respite hopes
[AtoZ into Korean mind] Death & denial: Why Koreans refuse to contemplate the end
Hospitals experience disruptions on extended doctors' walkout
Parents of 7 first to receive W10m for childbirth in Seoul
G7 leaders decry N. Korea's exports of ballistic missiles to Russia
Woman jailed for extortion, assault of celebrity she dated for 10 days
Tire falls off truck and hits bus; 2 killed, 12 injured
Occult thriller 'Exhuma' reaches 1m ticket sales in record time
Medical drama's prospects hit as doctors lose sympathy
Fewer S. Koreans take parental leave; more opt to reduce work hours
Samsung Bioepis seeks approval for Humira biosimilar in KoreaBy 이지윤
Published : Sept. 26, 2016 - 15:02
According to industry sources on Sept. 26, the biopharma development unit of Samsung Group has recently submitted its application to the Korean authorities for the sales approval of its Humira biosimilar, called SB5.
Sources said the final approval could be granted in the first half of next year.
Humira, together with Enbrel and Remicade, are considered the top-selling biotech drugs that block chemicals linked to inflammation.
Samsung Bioepis is already selling its own biosimilar versions of Enbrel and Remicade in South Korea and Europe.
Adding to the three drugs, the company is also waiting for the approval for its SB3, a biosimilar for Roche’s breast cancer drug Herceptin, in South Korea.
By Lee Ji-yoon (email@example.com)
Govt. says trainee doctors won't be held accountable if they return to work by Thursday
Death & denial: Why Koreans refuse to contemplate the end
Anti-Yoon vs anti-establishment: Main parties’ election strategies take shape